Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava Sciences announced Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...

A decade ago, researchers introduced a new model for studying Alzheimer's disease. Known as "Alzheimer's in a dish," the ...

A future treatment for Alzheimer disease may involve a nasal spray. Researchers at Università Cattolica and Fondazione ...

IGC Pharma, Inc. reported additional interim data from its clinical trial evaluating IGC-AD1 for agitation in Alzheimer’s.

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...

While there is no cure for Alzheimer's disease, drug treatments aimed at slowing disease progression and alleviating symptoms ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

There's no cure for this disease, but now there is some hope for people and their families who are battling the illness in ...